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Sodium-glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists
(GLP-1RAs) are antihyperglycaemic agents with weight-lowering effects. The efficacy and safety of
the SGLT2 inhibitor canagliflozin as add-on therapy in Japanese patients with type 2 diabetes melli-
tus (T2DM) and inadequate glycaemic control with a GLP-1RA (≥12 weeks) were evaluated in this
phase IV study. Patients received canagliflozin 100 mg once daily for 52 weeks. Efficacy endpoints
included change in glycated haemoglobin (HbA1c), fasting plasma glucose (FPG), body weight, sys-
tolic blood pressure (SBP) and HDL cholesterol from baseline to week 52. Safety endpoints
included adverse events (AEs), hypoglycaemia and laboratory tests. Of the 71 patients treated with
canagliflozin, 63 completed the study. At 52 weeks, HbA1c was significantly reduced from baseline
(−0.70%; paired t test, P < .001). Significant changes were also observed in FPG (−34.7 mg/dL),
body weight (−4.46%), SBP (−7.90 mm Hg), and HDL cholesterol (7.60%; all P < .001). The inci-
dence of AEs, adverse drug reactions and hypoglycaemia was 71.8%, 32.4% and 9.9%, respectively.
All hypoglycaemic events were mild. These findings suggest that the long-term combination of
canagliflozin with a GLP-1RA is effective and well tolerated in Japanese patients with T2DM.
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1 | INTRODUCTION
Obesity is a cause of insulin resistance and can lead to the develop-
ment and progression of type 2 diabetes mellitus (T2DM). While in
Western countries body mass index (BMI) ≥30 kg/m2 is considered
the threshold for obesity, the Japan Society for the Study of Obesity
defines it as a BMI ≥25 kg/m2, as the incidence of obesity-associated
chronic diseases, including T2DM, increases rapidly in patients with a
BMI ≥25 kg/m2 in Japan.1 While the mean BMI in the Japanese gen-
eral population has not increased over the past decade,2 that of
patients with T2DM has gradually increased to ~25 kg/m2; therefore,
the management of body weight in patients with T2DM has become
an important issue.3,4
In addition to their antihyperglycaemic effects, sodium-glucose co-
transporter-2 (SGLT2) inhibitors reduce body weight through the caloric
loss associated with increased urinary glucose excretion,5 while
glucagon-like peptide-1 receptor agonists (GLP-1RAs) promote weight
loss by decreasing appetite and delaying gastric emptying6; therefore,
combination therapy with a GLP-1RA and an SGLT2 inhibitor can
be suitable for patients with T2DM who are overweight or obese.
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In non-Japanese patients with T2DM, this combination therapy resulted
in improved glycaemic control and weight loss in randomized controlled
trials.7,8 Although two long-term, open-label studies in Japanese patients
with T2DM have been conducted, metabolic variables (body weight,
blood pressure and lipid profile) warrant further investigation.9,10
Type 2 diabetes is a risk factor for cardiovascular disease, and
cardiovascular outcome studies investigating the use of SGLT2 inhibi-
tors (EMPA-REG OUTCOME, CANVAS programme) and GLP-1RAs
(LEADER, SUSTAIN-6) showed reduced risks of the composite end-
points of cardiovascular death, non-fatal myocardial infarction, or
non-fatal stroke.11,12 Furthermore, the CANVAS programme and a
subanalysis of the EMPA-REG OUTCOME and LEADER trials sug-
gested that SGLT2 inhibitors and GLP-1RAs have renal protective
effects.12 These data suggest that the combined use of SGLT2 inhibi-
tors and GLP-1RAs is an optimal approach.
The aim of the present study was to investigate the long-term
efficacy and safety of canagliflozin, an SGLT2 inhibitor, as add-on
therapy in Japanese patients with T2DM inadequately controlled
with the GLP-1RA liraglutide plus exercise and diet therapy.
2 | MATERIALS AND METHODS
Details of the patients' inclusion/exclusion criteria, sample size and sta-
tistical analyses are provided in the Supporting Information (File S2
Supplementary Methods). Briefly, Japanese patients with T2DM with
inadequate glycaemic control despite receiving GLP-1RA monotherapy
in conjunction with diet and exercise therapy were eligible.
2.1 | Ethics
This trial complied with the Declaration of Helsinki, Japanese Law for
Ensuring the Quality, Efficacy, and Safety of Drugs and Medical
Devices, Good Clinical Practice, and the approved study protocol. The
procedures were approved by the institutional review boards at all par-
ticipating institutions, which are listed in the Supporting Information
(File S1). The trial was registered at ClinicalTrials.gov: NCT02227849.
2.2 | Trial design and treatment
This was a multicentre, non-randomized, uncontrolled, open-label
post-marketing (phase IV) study conducted in Japan. The treatment
period was 52 weeks, and all patients received liraglutide (constant
dose 0.6 or 0.9 mg, the approved maximum dose in Japan) with diet
and exercise therapy for ≥12 weeks prior to the treatment period,
throughout the treatment period, and after the treatment period.
Post-treatment follow-up lasted for 2 weeks from the day after the
end of the treatment period or from the day after treatment discon-
tinuation. During the treatment period, canagliflozin 100 mg was
administered once daily before breakfast, based on the approved dos-
age and administration. There was no dose titration or adjustment.
2.3 | Outcomes
The major efficacy endpoints were: change in HbA1c and the pro-
portions of patients with HbA1c <7% (53 mmol/mol) and <8%
(64 mmol/mol); changes in fasting plasma glucose (FPG), body
weight and blood pressure. Other efficacy endpoints are listed in
the Supporting Information (Appendix S1 Supplementary Methods).
Additionally, a systolic blood pressure (SBP)-stratified subgroup
analysis of blood pressure was performed.
The specific safety endpoints were adverse events (AEs), hypo-
glycaemia, laboratory tests, 12-lead ECG and vital signs. Investigators
and sub-investigators judged whether an AE was related to the
study drug.
3 | RESULTS
3.1 | Patient flow and baseline characteristics
Of the 87 patients who granted consent, 16 withdrew before the
treatment period, resulting in 71 patients entering the treatment
period (File S3 and File S4).
3.2 | Efficacy
Canagliflozin significantly reduced HbA1c at all time points (P < .001),
with a mean change of −0.70% from baseline to week 52 (LOCF,
95% confidence interval [CI] −0.89, −0.51; Figure 1A). At week
52 (LOCF), the proportions of patients achieving an HbA1c <7.0%
(53 mmol/mol) and <8.0% (64 mmol/mol) were 22.06% (95% CI
12.90, 33.76) and 44.44% (95% CI 27.94, 61.90), respectively. Simi-
larly, FPG was significantly reduced at week 52 (LOCF; −34.7 mg/dL
[95% CI −43.7, −25.7]) and at all time points (all P < .001; Figure 1B).
The mean change in body weight at week 52 (LOCF) was −3.29 kg
(95% CI −3.85, −2.73) or −4.46% (95% CI −5.22, −3.69; File S5 and
Figure 1C). The mean change in SBP was −7.90 mm Hg (95% CI
−10.70, −5.10; Figure 1D). In the sub-group analysis, SBP at baseline
in the non-hypertensive group (SBP <130 mm Hg, n = 34) was
120.46 mm Hg and the change from baseline at week 52 was
−1.92 mm Hg, failing to show a significant change. The SBP at base-
line in the hypertensive group (SBP ≥130 mm Hg, n = 37) was
139.52 mm Hg and the change from baseline at week 52 was
−13.39 mm Hg, a significant decrease (P < .001). Additional efficacy
results are included in the Supporting Information (Appendix S2, File
S5 and S6).
3.3 | Safety
Adverse drug reactions (ADRs)/AEs and ADRs occurred in 32.4% and
71.8% of patients, respectively (Table 1). Serious AEs occurred in
7.0% of patients. No serious ADRs occurred. AEs and ADRs that led
to treatment discontinuation were reported in 5.6% and 1.4% of
patients, respectively. There were no deaths.
Hypoglycaemia occurred in 9.9% of patients (Table 1). All
reported cases of hypoglycaemia were mild. The incidences of vulvo-
vaginal candidiasis, osmotic diuresis and subcutaneous tissue disor-
ders were 7.1%, 12.7% and 8.5%, respectively. The incidence rate of
other AEs of special interest was <5.0%. Additional safety results are
included in the Supporting Information (File S7 and S8).
HARASHIMA ET AL. 1771
Week W0 W4 W8 W12 W16 W20 W24 W28 W32 W36 W40 W44 W48 W52 LOCF
(B)
(A)
70N 71 70 69 69 66 66 66 65 63 63 63 63 63 71
Week W0 W4 W8 W12 W16 W20 W24 W28 W32 W36 W40 W44 W48 W52 LOCF
69 69N 71 69 69 65 66 66 64 63 63 63 63 63 70
Week W0 W4 W8 W12 W16 W20 W24 W28 W32 W36 W40 W44 W48 W52 LOCF
(C)
(D)
69N 71 69 69 69 65 66 66 64 63 63 63 63 63 70
Week W0 W4 W8 W12 W16 W20 W24 W28 W32 W36 W40 W44 W48 W52 LOCF
70 70N 71 69 69 66 66 66 65 63 63 63 63 63 71
FIGURE 1 A, Change in glycated haemoglobin (HbA1c). B,
Change in fasting plasma glucose. C, Percentage change in
body weight. D, Change in systolic blood pressure over
time (full analysis set). Data represent means 95%
confidence intervals. W0 = first day of the treatment
period; WX = week X of the treatment period. *HbA1c
(mmol/mol) = 10.93 × NGSP(%) — 23.52. Plasma glucose
conversion factor: 1 mg/dL = 0.0555 mmol/L.
*P < .01; **P < .001
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4 | DISCUSSION
Among Japanese patients with T2DM inadequately controlled with a
GLP-1RA plus exercise and diet therapy, add-on therapy with canagli-
flozin showed not only an antihyperglycaemic effect, but also a
reduction in body weight and blood pressure. These effects were sus-
tained without being diminished over the 52-week period. The
degree of reduction in HbA1c, FPG levels and body weight was simi-
lar to that observed in previous trials of canagliflozin, administered
alone or in combination with other antihyperglycaemic drugs.13–15
Moreover, SBP was markedly reduced, without an increase in
pulse rate.
The GLP-1RA class of drugs improve glycaemic control by pro-
moting insulin secretion and suppressing glucagon secretion.6 Fur-
thermore, they reduce body weight by suppressing appetite and
gastric emptying, reduce blood pressure, and improve patients' lipid
profiles; however, they increase heart rate.6 SGLT2 inhibitors not
only exert antihyperglycaemic effects, but can also reduce body
weight by enhancing urinary glucose excretion.5 Additionally, they
can reduce blood pressure and improve lipid profiles, and, unlike
GLP-1RAs, they do not increase heart rate.5 In the present study,
canagliflozin showed similar effects to its monotherapy, even after
the effects of liraglutide stabilized; therefore, canagliflozin added
onto GLP-1RA monotherapy may have acted in a complementary
manner.
Good glycaemic control, in addition to the control of body
weight, blood pressure and lipids, is important in preventing the
development of diabetes-related microangiopathy and macroangiopa-
thy; however, goals for these variables may not be achieved in all
patients.16 In the present study, along with antihyperglycaemic
effects, beneficial effects on risk factors for complications were also
observed. Canagliflozin reduced body weight in patients receiving a
GLP-1RA for ≥12 weeks. It has been suggested that chronic glycos-
uria by SGLT2 inhibitors causes a compensatory increase in energy
intake.17 In addition to effects on gastric emptying, GLP-1RAs also
suppress appetite, resulting in weight loss from decreased food
intake.6 Taken together, the beneficial effects on body weight in the
present study, along with the differing mechanisms of the two drug
classes, support the combined use of SGLT2 inhibitors and GLP-1RAs
in patients with T2DM and obesity.
Significant reductions in blood pressure were observed in the
present study; nevertheless, the baseline values of blood pressure
were close to the therapeutic target for hypertension treatment in
patients with T2DM in Japan (<130/80 mm Hg). The possible mecha-
nisms of the antihypertensive effects of SGLT2 inhibitors may be
based on diuresis, body weight reduction, nephron remodelling and
reduced arterial stiffness, but the exact mechanisms are not fully
understood.18
Additionally, the present study found increased HDL cholesterol
levels and decreases in triglyceride and serum uric acid levels
(Supporting Information). These effects are generally known to con-
tribute to a reduced risk of cardiovascular events.16 Moreover, the
beneficial effects on fasting proinsulin/C-peptide ratio and updated
homeostatic model assessment of β-cell function (HOMA2-%B) in this
study (Supporting Information) suggest an improvement in pancreatic
β-cell function. This may be attributable to the alleviation of glucose
toxicity by the SGLT2 inhibitor and the reduced load on pancreatic β
cells in insulin secretion.5 Taken together, combination therapy of an
SGLT2 inhibitor and a GLP-1RA may provide additional clinical bene-
fits compared with monotherapy with either GLP-1RAs or SGLT2
inhibitors.
With regard to safety, there were no serious ADRs or deaths,
and ~10% of patients experienced hypoglycaemia. Other AEs of spe-
cial interest observed in ≥5% of patients during the study were vulvo-
vaginal candidiasis, osmotic diuresis and skin and subcutaneous
disorders. All these events were mild and did not lead to discontinua-
tion. These findings are in line with other Japanese studies of canagli-
flozin therapy,13–15 and there were no additional safety concerns.
Furthermore, in their joint position statement, the American Diabetes
Association and European Association for the Study of Diabetes have
urged caution in the use of combinations of multiple therapies
because of issues relating to ADRs, drug interactions, patient adher-
ence and increased costs.19 The cost burden of managing T2DM and
obesity is increasing.20,21 While the cost of the combination therapy
described in the present study is high, this may be offset by prevent-
ing the development of complications because of the improvement in
risk factors. There is a clear need, however, for further cost-
effectiveness studies.
TABLE 1 Summary of adverse events, adverse drug reactions and
adverse events of special interest (safety analysis set)





AEs 51 (71.8) 169 59.9-81.9
ADRs 23 (32.4) 41 21.8-44.5
Serious AEs 5 (7.0) 5 2.3-15.7
Serious ADRs 0 0 0.0-5.1
AEs leading to discontinuation 4 (5.6) 4 1.6-13.8
ADRs leading to discontinuation 1 (1.4) 1 0.0-7.6
Death 0 0 0.0-5.1
Adverse events of special interest
Hypoglycaemia 7 (9.9) 7 4.1-19.3
Urinary tract infection 1 (1.4) 1 –
Male genital infection 0 (0.0) 0 –
Vulvovaginal candidiasisb 2 (7.1)2 2 –
Osmotic diuresis 9 (12.7) 15 –
Volume depletion 1 (1.4) 1 –
Fracture 1 (1.4) 1 –
Skin and subcutaneous
tissue disorders
6 (8.5) 6 –
Malignant neoplasm 2 (2.8) 2 –
Cardiovascular-related events 0 (0.0) 0 –
Hepatic function impairment 0 (0.0) 0 –
Renal dysfunction 0 (0.0) 0 –
Abbreviations: ADR, adverse drug reaction; AE, adverse event; CI, confi-
dence interval.
a Number (%) of patients with incidents.
b In women only.
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The present study had a number of limitations, including its
open-label nature and the fact that it was limited to Japanese
patients, making generalization to other settings difficult. In addition,
body composition was not evaluated in the present study; however,
the reduction in waist circumference may suggest a decrease in
visceral fat.
In summary, the present study indicates that long-term therapy
with canagliflozin as add-on therapy to a GLP-1RA (52 weeks) is
effective and well tolerated in Japanese patients with T2DM. It also
suggests that combination therapy with an SGLT2 inhibitor and a
GLP-1RA could be a useful therapeutic option for overweight and/or
obese patients with T2DM. Recent clinical trials suggest that both
SGLT2 inhibitors and GLP-1RAs have cardiovascular and renal pro-
tective effects12; therefore, combination therapy may also be a bene-
ficial treatment option for patients with T2DM with multiple risk
factors for complications. Additional studies in larger groups of
patients are recommended to further explore these findings.
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